Thrombosis and Haemostasis

Article	Citations
Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and Rivaroxaban	311
Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease	281
Binding Promiscuity of Therapeutic Factor VIII	85
Utility of Sepsis-induced Coagulopathy among Disseminated Intravascular Coagulation Diagnostic Criteria: A Multicenter Retrospective Validation Study	73
	67
Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives	52
Inhibition of IP3 (Inositol 1,4,5-Trisphosphate) Receptors Retards SARS-CoV-2-Induced Endothelial von Willebrand Factor Secretion and Thrombosis	51
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial	47
Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials	43
Factor VIIa–Antithrombin Complexes are Increased in Asthma: Relation to the Exacerbation-Prone Asthma Phenotype	40
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel	40
Clinical and Genetic Characterization of 51 Patients with Congenital Fibrinogen Disorders from China	38
Of Mice and Man: The Unwinding of CLEC-2 as an Antithrombotic Target?	35
Does Fibrinolytic Strategy of Pulmonary Embolism International THrOmbolysis (PEITHO)-3 Trial Need More Strong Evidence?	35
	34
	33
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials	32
Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke	32
Heparin and Direct Oral Anticoagulants have Different Effects on the Phases of Activation and Spatial Spread of Blood Coagulation	32
DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation	31
MicroRNAs as Biomarkers for Personalized Antiplatelet Therapy	30
Association between Clot Waveform Analysis Parameters and the Severity of Liver Cirrhosis	29
Thrombosis and Haemostasis 2024 Editors' Choice Papers	29
Significant Major Bleeding in Hospitalized Patients with COVID-19 Receiving Thromboprophylaxis	29
Roles of ROCK/Myosin Pathway in Macrothrombocytopenia in Bernard–Soulier Syndrome	28

Newborn and Pediatric Reference Intervals for Coagulation Assays Using Novel Reagents	28
A Systematic Review of Anticoagulation Strategies for Patients with Atrial Fibrillation in Critical Care	27
Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites	27
Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin	27
Relationship Between Screening-Detected Atrial Fibrillation and Blood Pressure Levels in Elderly Hypertensive Patients: The OMRON Heart Study	27
Risk Factors for Postdischarge Major Thromboembolism and Mortality in Hospitalized Patients with COVID-19 with Cardiovascular Comorbidities: Insights from the CORE-19 Registry	25
Home Treatment Compared to Initial Hospitalization in Normotensive Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis	25
The Optimal Management for People with Acute Stroke and Minor Deficits: Intravenous Thrombolysis or Medical Management?	23
Quantitative 2D 1H, 13C HSQC NMR Spectroscopy for the Determination of Chondroitin Sulfate and Dermatan Sulfate Content in Danaparoid Sodium	23
Platelet Activation is Upregulated in Cirrhotic Patients with Portal Vein Thrombosis	23
A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease	22
Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity	22
Unraveling the Molecular Pathogenesis of Protein C Deficiency–Associated VTE: Insights from Protein C Mutations C238G and R189W in Thai Patients	21
Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19	20
Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk	20
Response: Does Fibrinolytic Strategy of Pulmonary Embolism International ThrOmbolysis (PEITHO)-3 Trial Need More Strong Evidence?	19
Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score	19
Mortality of Escalation and Modulation Antithrombotic Therapy in Coronary Artery Disease Patients: A Meta-analysis of Randomized Controlled Trials	19
Residual Venous Obstruction as an Indicator of Clinical Outcomes following Deep Vein Thrombosis: A Management Study	19
Platelet-Released Extracellular Vesicle Characteristics Differ in Chronic and in Acute Heart Disease	18
Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis	18
Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis	18
	17
Incidence of Pregnancy-Associated Venous Thromboembolism: Second Nationwide Study	17
	17
Inflammatory Markers Differentiate Cerebral Venous Sinus Thrombosis from Mimics	17
Proteomic Characterization of Plasma in Lemierre's Syndrome	17
Not Just CTEPH: A Narrative Review on the Spectrum Approach to Postpulmonary Embolism Conditions	16
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study	16
Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response	16
	16
	16
Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation	16
Rupatadine Treatment Is Associated with Atherosclerosis Worsening and Altered T Lymphocyte Recruitment	16
Knockdown and Knockout of Tissue Factor Pathway Inhibitor in Zebrafish	16
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation	16
Decreased Platelet Reactivity and Function in a Mouse Model of Human Pancreatic Cancer	15
Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus	15
The ADA (Age-D-Dimer-Albumin) Score to Predict Thrombosis in SARS-CoV-2	15
Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism	14
Shear Stress Promotes Remodeling of Platelet Glycosylation via Upregulation of Platelet Glycosidase Activity: One More Thing	14
Persistent and Late-Onset Disseminated Intravascular Coagulation Are Closely Related to Poor Prognosis in Patients with Sepsis	14
The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population	14
Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction	14
COVID-19 Patients Putting on the Brakes with PAR1 Autoantibodies	14
The Effect of Cytokine Adsorption on Leukocyte and Platelet Activation after Extracorporeal Cardiopulmonary Resuscitation	14
miR-204-5p and Platelet Function Regulation: Insight into a Mechanism Mediated by CDC42 and GPIIbIIIa	14
Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention	14
Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study	14
Predicting Bleeding in Cancer-Associated Venous Thromboembolism: Another Milestone Achieved	14

Atherosclerotic Plaque VASA Vasorum in Diabetic Macroangiopathy: WHEN IS Important, but also HOW IS Needed	14
Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial	13
Plasma Homocysteine in Behcet's Disease: A Systematic Review and Meta-Analysis	13
COVID-19 and Long-COVID Thrombosis: From Clinical and Basic Science to Therapeutics	13
The Association between Obstructive Sleep Apnea and Venous Thromboembolism: A Bidirectional Two-Sample Mendelian Randomization Study	13
Characterization of the Role of Integrin α5β1 in Platelet Function, Hemostasis, and Experimental Thrombosis	13
Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism	13
Atherosclerotic Autoantigen ALDH4A1 as a Novel Immunological Indicator for Plaque Erosion in Patients with ST Segment Elevated Myocardial Infarction	13
Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders	13
Compromised PAR1 Activation—A Cause for Bleeding in XMEN?	13
Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial	13
Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study	13
Exploring Causal Relationships between Circulating Inflammatory Proteins and Thromboangiitis Obliterans: A Mendelian Randomization Study	13
Antithrombin Resistance Rescues Clotting Defect of Homozygous Prothrombin-Y510N Dysprothrombinemia	12
Thrombosis and Thrombocytopenia Syndrome Causing Isolated Symptomatic Carotid Occlusion after Covid-19 Vaccine	12
Ticagrelor Therapy Modifications after Acute Coronary Syndrome: An Ever-Evolving Issue	12
“Novel Clinical Concepts in Thrombosis”: Integrated Care for Stroke Management—Easy as ABC	12
Unfavorably Altered Fibrin Clot Phenotype in Women Following Postpartum Hemorrhage of Unknown Cause: Effect of Lower Coagulation Factors	12
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A	11
The Rise of the Machines: Using Machine Learning to Assess Thrombosis and Bleeding Risks, and Optimizing Anticoagulation Strategies	11
Commentary: “No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study”	11
Reply to “Commentary: ‘No Genetic Causality between Tobacco Smoking and Venous Thromboembolism: A Two-Sample Mendelian Randomization Study’ ”	11
A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, a Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention	11
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial	11
	11
F11 Gene Duplication Causes Elevated FXI Plasma Levels and Is a Risk for Venous Thrombosis	11
Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit	11
The Hidden Culprit: Troubles with Enhanced Deglycosylation in Mechanical Circulatory Support	11
Platelet-Derived TGF-β1 Promotes Deep Vein Thrombosis	11
Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease	10
The Interaction Effect between Comorbidity Burden and Venous Thromboembolism on Mortality: A Nationwide Cohort Study	10
Tissue Factor Pathway–Driven Initial Thrombin Generation is Associated with Hypercoagulability in Obesity	10
	10
Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy	10
Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation	10
Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis	10
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer	10
Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis	10
Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis	10
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score	10
Inhibitor Formation in the Era of Novel Haemophilia Treatment—A Humanized Mouse Model to Answer Our Questions?	10
Obesity-Related Traits Mediate the Effects of Educational Attainment on the Risk of Varicose Veins, Venous Thromboembolism, and Phlebitis	10
Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry	10
The Hard Bargain of Anticoagulation after Intracranial Hemorrhage, in the Setting of Venous Thromboembolism: Between a Rock and a Hard Place	10
TARGET: A Major European Project Aiming to Advance the Personalised Management of Atrial Fibrillation-Related Stroke via the Development of Health Virtual Twins Technology and Artificial Intelligence	10
The Report of Community-Based and Government-Endorsed Screening Program of Atrial Fibrillation in Taiwan	10
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease	10
Validation of Risk Assessment Models Predicting Venous Thromboembolism in Inpatients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Multicenter Cohort Study in China	10
	9
Gene Correction of Wiskott–Aldrich syndrome iPS Cells Rescues Proplatelet Defects and Improves Platelet Size	9
	9
More on the Source of D-Dimer in COVID-19	9
The Effect of Increasing Factor X Levels on Emicizumab-Driven Coagulation Potential	9
Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment	9
	9
Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems	9
Monocyte Tissue Factor Expression: Lipopolysaccharide Induction and Roles in Pathological Activation of Coagulation	9
Pathophysiology of Antiphospholipid Syndrome	9
3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis	9
	9
Carbamylation is Instrumental in End-Stage Kidney Disease Coagulopathies: The Impact on von Willebrand Factor and Platelet Functionality	9
Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex	9
	9
A Trp11Arg Substitution in the β3 Signal Peptide Prevents Expression of αIIbβ3 in Patients with Glanzmann Thrombasthenia	9
Role of Membrane Lipid Rafts in MRP4 (ABCC4) Dependent Regulation of the cAMP Pathway in Blood Platelets	9
Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis	9
	8
Characterization of CD3+ T Lymphocytes in Human Coronary Thrombi with ST-segment Elevation Myocardial Infarction	8
A New Chapter Regarding Thrombosis Risk Assessment in Total Joint Replacement Patients	8
	8
Obesity and Pulmonary Embolism: Can We Dismantle the “Obesity Paradox”	8
	8
Potential of Sulodexide in the Treatment of Diabetic Retinopathy and Retinal Vein Occlusion	8
Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study	8
Untargeted Plasma Metabolomics and Gut Microbiome Profiling Provide Novel Insights into the Regulation of Platelet Reactivity in Healthy Individuals	8
Carotid Stenosis and Stroke: Medicines, Stents, Surgery—“Wait-and-See” or Protect?	8
Cardiac Repair after Myocardial Infarction is Controlled by a Complement C5a Receptor 1-Driven Signaling Cascade	7
Venous Thromboembolism Prophylaxis after Hematopoietic Cell Transplantation: Still a Challenge for Hematologists and Hemostasiologists	7
The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A	7
Exploring the Two-Way Link between Migraines and Venous Thromboembolism: A Bidirectional Two-Sample Mendelian Randomization Study	7

Small-Area Analysis of Treatment and Clinical Outcomes in Patients with Venous Thromboembolism in Denmark: A Nationwide Cohort Study	7
Visit-to-Visit Heart Rate Variability in the Prediction of Clinical Outcomes of Patients with Atrial Fibrillation	7
Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design	7
Treatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry	7
Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials	7
The Story of the Fibrin(ogen) αC-Domains: Evolution of Our View on Their Structure and Interactions	7
Changes in Coagulation Factor XI Activity Levels in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI	7
Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis	7
Circulating Levels of Low-Density Granulocytes and Cell-Free DNA as Predictors of Cardiovascular Disease and Bone Deterioration in SLE Patients	7
Venous Thromboembolism in Women of Childbearing Age: Insights from the START Registry	7
Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells	7
Dynamics of Thrombogenicity and Platelet Function and Correlation with Bleeding Risk in Patients Undergoing M-TEER Using the PASCAL System	7
Reflections on World Thrombosis Day 2024	7
Monocyte Subsets in Cardiovascular Disease: A Biomarker Perspective	7
Enoxaparin for Long-Term Therapy of Venous Thromboembolism in Patients with Cancer and Renal Insufficiency	7
A Rollercoaster Plunge into 2022	7
Hypercoagulability on Thromboelastography Can Predict the Functional Outcomes in Patients with Acute Ischemic Stroke	7
Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?	7
Strategies for Tailored Antiplatelet Therapy after Percutaneous Coronary Intervention: Unraveling Complexities, Embracing Nuances	7